Eli Lilly and news
The WiseView Research desk's stories that name Eli Lilly and, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The LLY page →
- HeadlineHere's How Much Eli Lilly Stock Is Expected to Move After Earnings
- Headline$10,000 Invested in Eli Lilly 5 Years Ago Would Be Worth This Much Today
- HeadlineEli Lilly international business chief Jonsson to retire; Yuffa to head global markets unit
- HeadlineBuy, Sell or Hold LLY Stock? Key Factors to Watch Ahead of Q3 Earnings
- HeadlineLilly declares fourth-quarter 2026 dividend
- HeadlineLLY vs. MRK: Which Stock Offers the More Compelling Investment Case?
- HeadlineLilly (LLY) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
- HeadlineEli Lilly (LLY) Price Forecast: Breakout Strengthens Ahead of Earnings
- HeadlineLilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020
- HeadlineInvestors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
- HeadlineHere's What I'm Planning With My Eli Lilly Position
- HeadlineStock Market Midday, Oct. 20: Blue Chips Rally, Eli Lilly Gains 5%
- HeadlineIf Eli Lilly Grows At 10% a Year, Here's What $1,000 Becomes By 2030
- HeadlineEli Lilly (LLY) Stock Dips While Market Gains: Key Facts
- HeadlinePrediction: Eli Lilly Stock Could Be a Long-Term Winner for Investors
- HeadlineIs Eli Lilly Stock a Buy Right Now?
- HeadlineMetis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech
- HeadlineLilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis
- HeadlineLilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress
- HeadlineForget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher
- HeadlineLilly confirms date and conference call for third-quarter 2026 financial results announcement
- HeadlineNew composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year
- HeadlineHere's Why Eli Lilly (LLY) Fell More Than Broader Market
- HeadlinePrediction: Eli Lilly Could Have More Room to Grow Than Its Valuation Suggests
- CongressRo Khanna bought $1,001 - $15,000 of LLY
- HeadlineEli Lilly's Biggest Shareholder Just Filed to Sell $347 Million of Stock
- HeadlineNew Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity
- HeadlineEli Lilly (LLY) Just Overtook the 50-Day Moving Average
- HeadlineEli Lilly To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Thursday
- HeadlineLilly's Worst Entry Points Were Its Most Hyped Approvals Mounjaro and Zepbound
- HeadlineEli Lilly: Dominance Has A Price
- HeadlineEli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
- HeadlineLilly Expands Oncology Footprint With FDA Win for Pancreatic Cancer Drug
- HeadlineFDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting
- HeadlineLilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions
- HeadlineEli Lilly Just Announced Something Big. Here's What It Means for Investors.
- HeadlineLilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
- HeadlineLLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies
- HeadlinePrediction: Eli Lilly Could Be the Next $2 Trillion Drugmaker
- HeadlineWill Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?
- HeadlineEli Lilly (LLY) Suffers a Larger Drop Than the General Market: Key Insights
- HeadlineExperimental Lilly combination drug tops Zepbound in weight-loss trial
- HeadlineA next-generation weight-loss drug from Eli Lilly, when combined with Zepbound, helped people lose substantially more weight than Zepbound alone, according to a new study
- HeadlineNew Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis
- HeadlineLilly's experimental drug cuts weight by 21% in diabetes trial
- HeadlinePrediction: Eli Lilly's Next Growth Wave Could Surprise Investors
- HeadlineWall Street Breakfast Podcast: Federal Boost For Navitas
- HeadlineLilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
- CongressJohn Boozman sold $1,001 - $15,000 of LLY
- CongressMichael Rulli bought $1,001 - $15,000 of LLY
- CongressTommy Tuberville sold $15,001 - $50,000 of LLY
- CongressDan Newhouse sold $1,001 - $15,000 of LLY
- CongressRo Khanna bought $1,001 - $15,000 of LLY
- CongressGilbert Cisneros bought $50,001 - $100,000 of LLY
- CongressByron Donalds bought $1,001 - $15,000 of LLY
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.